Sendai, Japan

Masao Tada

This inventor holds 1 USPTO granted patent. Top assignee: Mitsui Pharmaceuticals, Inc.. Active years: 1976.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masao Tada. Retrieved from https://idiyas.com/inventor/masao-tada-qmzzgp29

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1976

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Masao Tada

Introduction

Masao Tada is a notable inventor based in Sendai, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in cancer therapy. His work focuses on developing effective antimetabolites that can aid in the treatment of mammary gland and gastrointestinal cancers.

Latest Patents

Masao Tada holds a patent for 5-Fluorouracil derivatives. This patent, represented by the formula ##SPC1##, includes compounds where R can be arylcarbonyl, substituted arylcarbonyl, heterocyclic carbonyl, alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, heterocyclic sulfonyl, or alicyclic sulfonyl. These derivatives are recognized for their effectiveness as antimetabolites in cancer therapy.

Career Highlights

Tada is currently associated with Mitsui Pharmaceuticals, Inc., where he continues to innovate and develop new therapeutic solutions. His work has been instrumental in advancing cancer treatment options, showcasing his dedication to improving patient outcomes.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Masao Tada's contributions to the field of pharmaceuticals, particularly through his patent on 5-Fluorouracil derivatives, highlight his role as an influential inventor in cancer therapy. His ongoing work at Mitsui Pharmaceuticals, Inc. continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…